Contrasting XOMA Royalty (NASDAQ:XOMA) & BioHarvest Sciences (NASDAQ:BHST)

XOMA Royalty (NASDAQ:XOMA) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares XOMA Royalty and BioHarvest Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	45.75%	10.32%	3.49%
BioHarvest Sciences	-36.33%	-1,041.86%	-36.06%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for XOMA Royalty and BioHarvest Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	1	2	3	0	2.33
BioHarvest Sciences	1	0	3	0	2.50

XOMA Royalty presently has a consensus price target of $61.60, suggesting a potential upside of 114.56%. BioHarvest Sciences has a consensus price target of $13.00, suggesting a potential upside of 204.45%. Given BioHarvest Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe BioHarvest Sciences is more favorable than XOMA Royalty.

Earnings & Valuation

This table compares XOMA Royalty and BioHarvest Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$12.57 million	27.19	-$13.82 million	$1.46	19.66
BioHarvest Sciences	$32.72 million	2.14	-$12.91 million	($0.68)	-6.28

BioHarvest Sciences has higher revenue and earnings than XOMA Royalty. BioHarvest Sciences is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

XOMA Royalty has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Institutional and Insider Ownership

95.9% of XOMA Royalty shares are owned by institutional investors. 9.1% of XOMA Royalty shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

XOMA Royalty beats BioHarvest Sciences on 8 of the 13 factors compared between the two stocks.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.